NASDAQ:OBIO Orchestra BioMed Q3 2025 Earnings Results & Report $5.76 +0.04 (+0.61%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more. Orchestra BioMed missed analyst earnings expectations but beat on revenue in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$0.40 versus the -$0.38 consensus estimate, while revenue of $0.86 million topped the $0.74 million estimate by $0.12 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 10, 2025TimeBefore Market OpensConference Call7:00 AM ET Orchestra BioMed EPS ResultsActual EPS-$0.40Consensus EPS -$0.38Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersOrchestra BioMed Revenue ResultsActual Revenue$0.86 millionExpected Revenue$0.74 millionBeat/MissBeat by +$120.00 thousandYoY Revenue GrowthN/AUpcoming EarningsOrchestra BioMed's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Orchestra BioMed Q3 2025 Earnings FAQ Did Orchestra BioMed beat earnings estimates for Q3 2025? Orchestra BioMed (NASDAQ:OBIO) reported earnings of -$0.40 per share for Q3 2025, missing the consensus estimate of -$0.38. The report was announced on Monday, November 10, 2025. What was Orchestra BioMed's revenue for Q3 2025? Orchestra BioMed reported revenue of $0.86 million for Q3 2025, against a consensus estimate of $0.74 million. When is Orchestra BioMed's next earnings date? Orchestra BioMed's next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Orchestra BioMed on the company's earnings history page. Orchestra BioMed Earnings HeadlinesOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Stock Has Average Price Target of $13.17October 5, 2026 | americanbankingnews.comOrchestra BioMed (NASDAQ: OBIO) clears BACKBEAT target with Medtronic studyOctober 4, 2026 | americanbankingnews.comMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a contest offering its biggest holders a seat at dinner with the President. It's also about 97% below its peak. Because a memecoin doesn't benefit from good policy. It benefits from attention. The real winners of a pro-crypto Washington are the projects with actual businesses underneath them. Ones that get more valuable as rules get clearer, institutions get comfortable, and more money flows into the market.October 14 at 1:00 AM | Crypto 101 Media (Ad)Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Regeneron (REGN)October 3, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Biogen (BIIB)October 3, 2026 | theglobeandmail.comOrchestra BioMed (NASDAQ:OBIO) Insider Darren Sherman Sells 15,000 Shares of Company StockOctober 3, 2026 | americanbankingnews.comSee More Orchestra BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email. Email Address About Orchestra BioMedOrchestra BioMed (NASDAQ:OBIO) is a clinical-stage biomedical innovation company that develops transformative therapies and medical devices for patients with cardiovascular and other serious medical conditions. The company uses a partnership-driven business model, collaborating with medical device and pharmaceutical companies to advance products through clinical development and toward commercialization. Its lead programs include Virtue SAB, an investigational drug-device combination designed to deliver sirolimus to the vessel wall without the use of a permanent drug-eluting implant. The product is being developed for vascular applications, including the treatment of stenosis in arteriovenous fistulas used for hemodialysis. Orchestra BioMed is also developing BackBeat Cardiac Neuromodulation Therapy, an investigational device-based treatment intended to provide sustained reductions in blood pressure through electrical modulation of the autonomic nervous system. Orchestra BioMed was formed through a business combination with ARYA Sciences Acquisition Corp. IV and began trading on the Nasdaq under the symbol OBIO in January 2023. The company is led by founder and Chief Executive Officer David Hochman and conducts its development activities through a combination of internal operations, clinical research organizations and strategic collaborators. Its programs are intended for global markets, with clinical and commercial development supported by international partnerships.View Orchestra BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
